高血压和心力衰竭

Q4 Medicine Open Hypertension Journal Pub Date : 2020-01-01 DOI:10.15713/INS.JOHTN.0210
M. Rao, S. Dhanse
{"title":"高血压和心力衰竭","authors":"M. Rao, S. Dhanse","doi":"10.15713/INS.JOHTN.0210","DOIUrl":null,"url":null,"abstract":"Hypertension is defined as blood pressure above 140/90 mmHg and is a leading cause for the development of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).[1] Although equally prevalent in both the forms of heart failure, it remains more common in HFpEF patients with prevalence of up to 90%, compared to HFrEF.[2-4] Various guidelines have recommended not only different staging systems for hypertension but also the target blood pressure (BP) goals and therapeutic drug usage in specified populations. Although the target BP goals and therapeutic strategies for BP control in HF patients have been mentioned in different guidelines, robust data are still lacking. Most of the recommendations for optimal BP control in HF patients have been extrapolated from other high-risk populations where intensive BP control showed better long-term cardiovascular (CV) outcomes, however, at an increased risk of adverse effects. Chronic hypertension causes pressure overload leading to ventricular hypertrophy which is initial compensatory mechanism and preserves cardiac output. Subsequently, the left ventricle (LV) dilates as remodeling occurs and LV starts to decompensate. Remodeling occurs due to activation of reninangiotensin system, sympathetic nervous system, and deposition of extracellular matrix. Diastolic dysfunction or the so-called HFpEF is the primary manifestation of hypertensive heart failure. It is only in the later stages that dilated cardiomyopathy leading to HFrEF sets in. Long-term prognosis is poor with increased mortality in hypertensive patients with HF. Treating hypertension can significantly reduce incident of HF and HF hospitalization, especially in old population.[5-7]","PeriodicalId":38918,"journal":{"name":"Open Hypertension Journal","volume":"29 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hypertension and Heart Failure\",\"authors\":\"M. Rao, S. Dhanse\",\"doi\":\"10.15713/INS.JOHTN.0210\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Hypertension is defined as blood pressure above 140/90 mmHg and is a leading cause for the development of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).[1] Although equally prevalent in both the forms of heart failure, it remains more common in HFpEF patients with prevalence of up to 90%, compared to HFrEF.[2-4] Various guidelines have recommended not only different staging systems for hypertension but also the target blood pressure (BP) goals and therapeutic drug usage in specified populations. Although the target BP goals and therapeutic strategies for BP control in HF patients have been mentioned in different guidelines, robust data are still lacking. Most of the recommendations for optimal BP control in HF patients have been extrapolated from other high-risk populations where intensive BP control showed better long-term cardiovascular (CV) outcomes, however, at an increased risk of adverse effects. Chronic hypertension causes pressure overload leading to ventricular hypertrophy which is initial compensatory mechanism and preserves cardiac output. Subsequently, the left ventricle (LV) dilates as remodeling occurs and LV starts to decompensate. Remodeling occurs due to activation of reninangiotensin system, sympathetic nervous system, and deposition of extracellular matrix. Diastolic dysfunction or the so-called HFpEF is the primary manifestation of hypertensive heart failure. It is only in the later stages that dilated cardiomyopathy leading to HFrEF sets in. Long-term prognosis is poor with increased mortality in hypertensive patients with HF. Treating hypertension can significantly reduce incident of HF and HF hospitalization, especially in old population.[5-7]\",\"PeriodicalId\":38918,\"journal\":{\"name\":\"Open Hypertension Journal\",\"volume\":\"29 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Open Hypertension Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15713/INS.JOHTN.0210\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Hypertension Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15713/INS.JOHTN.0210","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

高血压被定义为血压高于140/90 mmHg,是发生射血分数降低(HFrEF)和射血分数保留(HFpEF)心力衰竭的主要原因尽管在两种形式的心力衰竭中同样普遍,但与HFrEF相比,它在HFpEF患者中更为常见,患病率高达90%。[2-4]各种指南不仅推荐了不同的高血压分期系统,而且还推荐了特定人群的目标血压(BP)目标和治疗药物使用。尽管在不同的指南中提到了心衰患者的血压目标和控制血压的治疗策略,但仍然缺乏可靠的数据。大多数关于心衰患者最佳血压控制的建议都是从其他高危人群中推断出来的,在这些人群中,强化血压控制显示出更好的长期心血管(CV)结局,然而,不良反应的风险增加。慢性高血压引起压力过载导致心室肥厚,这是初始代偿机制,可保持心输出量。随后,左心室(LV)随着重构的发生而扩张,并开始失代偿。由于肾血管紧张素系统、交感神经系统的激活和细胞外基质的沉积,重塑发生。舒张功能障碍或所谓的HFpEF是高血压性心力衰竭的主要表现。只有在晚期扩张型心肌病才会导致HFrEF。高血压合并心衰患者的长期预后较差,死亡率增高。治疗高血压可显著降低心衰发生率和住院率,尤其是老年人群[5-7]。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Hypertension and Heart Failure
Hypertension is defined as blood pressure above 140/90 mmHg and is a leading cause for the development of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).[1] Although equally prevalent in both the forms of heart failure, it remains more common in HFpEF patients with prevalence of up to 90%, compared to HFrEF.[2-4] Various guidelines have recommended not only different staging systems for hypertension but also the target blood pressure (BP) goals and therapeutic drug usage in specified populations. Although the target BP goals and therapeutic strategies for BP control in HF patients have been mentioned in different guidelines, robust data are still lacking. Most of the recommendations for optimal BP control in HF patients have been extrapolated from other high-risk populations where intensive BP control showed better long-term cardiovascular (CV) outcomes, however, at an increased risk of adverse effects. Chronic hypertension causes pressure overload leading to ventricular hypertrophy which is initial compensatory mechanism and preserves cardiac output. Subsequently, the left ventricle (LV) dilates as remodeling occurs and LV starts to decompensate. Remodeling occurs due to activation of reninangiotensin system, sympathetic nervous system, and deposition of extracellular matrix. Diastolic dysfunction or the so-called HFpEF is the primary manifestation of hypertensive heart failure. It is only in the later stages that dilated cardiomyopathy leading to HFrEF sets in. Long-term prognosis is poor with increased mortality in hypertensive patients with HF. Treating hypertension can significantly reduce incident of HF and HF hospitalization, especially in old population.[5-7]
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Open Hypertension Journal
Open Hypertension Journal Medicine-Cardiology and Cardiovascular Medicine
自引率
0.00%
发文量
0
期刊最新文献
Implementation of a Resistant Hypertension Control Program in a Low-income Primary Care Setting in a High-Income Country: Lessons Learned and Global Applicability Troponin and B-type Natriuretic Peptides Biomarkers in the Management of Hypertension Hypertension in end-stage kidney disease Confirming a Diagnosis of "Hypertension" Sodium-glucose Co-transporter 2 Inhibitors and Blood Pressure Reduction among Patients with Diabetes, Cardiovascular Disease, Chronic Kidney Disease
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1